ATH Stock Overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
Earnings are forecast to decline by an average of 19.5% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Capture your thoughts, links and company narrative
Alterity Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.006|
|52 Week High||AU$0.021|
|52 Week Low||AU$0.006|
|1 Month Change||-25.00%|
|3 Month Change||-33.33%|
|1 Year Change||-62.50%|
|3 Year Change||-64.71%|
|5 Year Change||-86.67%|
|Change since IPO||-99.41%|
Recent News & Updates
We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn RateJun 28
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?Mar 07
We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash WiselyMay 16
Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn SituationJan 31
How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?Dec 09
|ATH||AU Biotechs||AU Market|
Return vs Industry: ATH underperformed the Australian Biotechs industry which returned 12.1% over the past year.
Return vs Market: ATH underperformed the Australian Market which returned -2.5% over the past year.
|ATH Average Weekly Movement||14.8%|
|Biotechs Industry Average Movement||10.6%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.6%|
|10% least volatile stocks in AU Market||3.2%|
Stable Share Price: ATH is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ATH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
Alterity Therapeutics Limited Fundamentals Summary
|ATH fundamental statistics|
Is ATH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATH income statement (TTM)|
|Cost of Revenue||AU$318.80k|
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0059|
|Net Profit Margin||-277.57%|
How did ATH perform over the long term?See historical performance and comparison